TME Pharma provides update about additional strategy

Berlin, Germany, July 29, 18h00 – **TME Pharma N.V. (Euronext Growth Paris: ALTME),** a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to share an update regarding its strategic repositioning.

- Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow at the holding company level
- Leveraging tax loss carry forwards
- Repositioning to enhance shareholder value creation, while maintaining the ultimate strategic focus on the development of NOX-A12 and NOX-E36 assets
- Gained access to the crypto-markets via newly established crypto brokerage account

TME Pharma NV is currently a holding company. Management will now implement and strengthen this structure through complementary, revenue-generating initiatives to cover operating costs. Parallel to its core biotechnology activities, the company is exploring potential acquisitions and partnerships in stable, profitable businesses. These efforts are aimed at creating a fundamentally profitable corporate structure in which revenues from non-core activities will support and strengthen the further development of its patented drug candidates, which remain the company's flagship products, NOX-A12 and NOX-E36.

The company holds over €150 million in tax loss carryforwards, which may provide financial benefit if profitable operations are established. A specialist firm is actively assessing opportunities for TME Pharma NV to use these tax assets.

Over the past two decades, TME Pharma has made significant investments in its development programs, resulting in promising scientific and clinical results. Shareholders have not yet been able to benefit from this strong fundamental performance, partly due to high dilution. Management's ambition is to break with this trend and has already taken measures to limit further dilution. As previously announced, the company successfully closed non-dilutive financing of €2.05 million in May, thanks in part to the support of the CEO, who subscribed to €600,000 of these bonds.As a next step, management believes that a diversified, profit-driven structure will provide a stronger foundation for unlocking the full potential of its key assets, NOX-A12 and NOX-E36, which ultimately represents true shareholder value.

As of June 30, a crypto-related investment was permitted under the current treasury policy. On July 24th, TME Pharma successfully registered with a leading European crypto broker. The company is actively evaluating opportunities in other crypto- and crypto related investments, with a disciplined approach to balancing risk and return.

Diede van den Ouden, Chief Executive Officer, stated:
"Our core objective remains consistent: we firmly believe that our key assets, NOX-A12 and NOX-E36, hold substantial value. The strategic framework we have now put in place is designed to create the optimal conditions for unlocking and enhancing shareholder value. TME Pharma is positioning itself to become a financially robust group, capable of making targeted, flexible investments in high-potential projects."

TME Pharma will seek shareholder approval as required for any potential transactions which emerge as part of the new strategy and issue press releases on all material developments.

For more information, please contact:

TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The company's lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The company's two lead assets are:

- NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and *TME Pharma* was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.

- NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.

The company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:

- Raising funds from alternative sources (€1,7 million raised in May 2025, including €500,000 from the new CEO)
- Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow at the holding company level
- Leveraging tax loss carry forwards
- Gaining exposure to digital assets via newly established crypto brokerage account

Further information can be found at: www.tmepharma.com.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.